DHEA has been one of the most-studied steroids in human research, with trial activity dating back to the late 1980s. The volume of literature is huge. The volume of well-powered, placebo-controlled literature is much smaller. Reading them with the same standards you would read a cardiovascular drug — adequate sample size, proper randomization, clinically meaningful endpoints — narrows the list of supported benefits considerably.
What the Research Actually Shows
A pragmatic summary, separated by quality of evidence:
- Strong evidence: Vaginal Prasterone for menopausal dyspareunia (FDA-approved indication).
- Moderate evidence: Oral DHEA replacement in primary or secondary adrenal insufficiency; modest libido and mood improvements in postmenopausal women with documented low DHEA-S.
- Weak/mixed evidence: General anti-aging effects; cognitive benefits in healthy older adults; meaningful improvements in body composition or insulin sensitivity.
- Insufficient evidence: Cardiovascular protection; cancer prevention; longevity extension.
Energy and Vitality
The “DHEA gives me my energy back” marketing rests on a small but real signal in one population — women and men with adrenal insufficiency or documented severe DHEA-S deficiency. In these patients, 25–50 mg/day produces clinically meaningful improvements in quality-of-life scores and subjective energy. The Cochrane review of DHEA in adrenal insufficiency cites this as the most robust finding in the literature.
In healthy adults with normal DHEA-S, the energy signal is much weaker. Several well-controlled trials have failed to find significant differences from placebo on standard fatigue scales.
Mood and Cognition
DHEA replacement in midlife and postmenopausal women with low DHEA-S has shown modest improvements in depression scores in several randomized trials. The effect size is smaller than standard antidepressant therapy but real, and DHEA is not a recognized first-line antidepressant.
Cognitive benefits in healthy older adults — memory, processing speed, executive function — have been studied repeatedly with inconsistent results. The honest summary is that DHEA does not appear to produce meaningful cognitive enhancement in healthy people.
Bone Density
DHEA appears to support bone mineral density via local conversion to estrogens in bone. Several controlled trials have shown small but statistically significant improvements in DEXA scores with 50 mg/day DHEA in postmenopausal women. The effect is roughly one-third to one-half the size produced by established osteoporosis therapy. DHEA is not a replacement for bisphosphonates or denosumab in women at high fracture risk, but it may be a reasonable adjunct in women with low baseline DHEA-S and borderline bone density.
Sexual Health and Libido
Sexual function is the area where the DHEA-women evidence is most useful, and where the distinction between local and systemic effects matters most.
- Local (vaginal Prasterone): Strong evidence for improvement in dyspareunia, dryness, and tissue health. FDA-approved.
- Systemic (oral DHEA) for desire: Modest improvements in postmenopausal women with low DHEA-S and hypoactive sexual desire disorder. Inconsistent in women with normal DHEA-S.
- Systemic DHEA vs testosterone for female libido: Transdermal testosterone has more consistent evidence for low female libido in current literature; many clinicians reach for testosterone before DHEA.
Skin and Aging
Skin contains the enzymatic machinery to convert DHEA locally into estrogens and androgens. Small controlled trials of oral and topical DHEA in postmenopausal women have shown modest improvements in skin hydration, sebum production, and epidermal thickness. The effects are real but small relative to retinoid therapy or established cosmeceutical interventions.
Muscle and Body Composition
DHEA is sometimes marketed for muscle mass and fat reduction. The controlled-trial evidence is unimpressive: most well-conducted studies have found small or non-significant effects on lean body mass and fat percentage at typical doses. The exceptions are in populations with adrenal insufficiency, where DHEA replacement contributes to body-composition normalization as part of broader hormone restoration.
Resistance training has substantially larger effect sizes on muscle mass than DHEA does, with a better safety profile.
7-Keto-DHEA: The Weight-Loss Variant
7-keto-DHEA (also called 7-oxo-DHEA or DHEA-7-ketosulfate) is a metabolite of DHEA produced in peripheral tissues. Unlike its parent compound, 7-keto-DHEA does not convert into testosterone or estradiol. It does not produce the androgenic side-effect profile of regular DHEA.
The marketing-vs-evidence picture for 7-keto:
- Several small trials (typically n=30–60) have shown modest thermogenic effects — small increases in resting metabolic rate.
- Weight-loss effect sizes in trials are typically 1–3 kg over 8 weeks, when paired with diet and exercise.
- Effects appear most reliably at 100 mg twice daily; lower doses show less consistent results.
- Long-term safety data are limited.
For readers who arrived at DHEA via a weight-loss search, 7-keto-DHEA is a more defensible target than regular DHEA — though the effect size is modest enough that calling it a “weight-loss supplement” overstates what the trials support. It does not, importantly, raise DHEA-S or testosterone.
Where the Evidence Plateaus
Several DHEA marketing claims are not supported by the current evidence base:
- Cardiovascular protection from DHEA supplementation in healthy adults.
- Cancer prevention or reduced cancer incidence with DHEA.
- Meaningful longevity extension.
- Reversing cognitive decline in healthy older adults.
- Curing or substantially preventing osteoporosis.
- Treating type 2 diabetes or improving insulin sensitivity at population scale.
The data on these claims is either negative, inconsistent, or too thin to support the marketing language attached to them.
Real Optimization: The Medical-Supervised Approach
“Optimization” is a popular framing in DHEA marketing. What it usually means in practice is replacing DHEA-S to a youthful target value. The evidence-based version of this is much more specific:
- Measure DHEA-S, estradiol, testosterone, SHBG, FSH, AM cortisol, thyroid panel at baseline.
- Identify which hormones are actually out of age-appropriate range (often not DHEA).
- Prioritize the intervention with the strongest evidence base for the woman’s specific symptoms.
- If DHEA is appropriate, dose to age-appropriate DHEA-S range, retest at 90 days, adjust.
This is the workflow that modern telehealth hormone practices have built around. It is structurally different from the supplement-aisle “buy a 25 mg bottle and see what happens” approach — and it is the path that the actual research literature most cleanly supports.